Publications by authors named "Haoxuan Ying"
Purpose: Lung adenocarcinoma (LUAD) significantly contributes to cancer-related mortality worldwide. The heterogeneity of the tumor immune microenvironment in LUAD results in varied prognoses and responses to immunotherapy among patients. Consequently, a clinical stratification algorithm is necessary and inevitable to effectively differentiate molecular features and tumor microenvironments, facilitating personalized treatment approaches.
View Article and Find Full Text PDFArticle Synopsis
- Homologous recombination deficiency (HRD) score indicates genomic instability and may affect prognosis and immune environment in nasopharyngeal carcinoma (NPC), although its significance is not well studied.
- Our research analyzed HRD status in NPC using three patient cohorts and various bioinformatics tools, revealing that individuals with no HRD were at higher risk for recurrence and mortality compared to those with HRD.
- The HRD group exhibited higher tumor mutational and neoantigen burdens and a non-inflamed immune microenvironment, suggesting they may have a better prognosis and offering insights for tailored treatment options.
Immune checkpoint inhibitors (ICIs) have made important breakthrough in anti-tumor therapy, however, no single biomarker can accurately predict their efficacy. Studies have found that tumor microenvironment is a key factor for determining the response to ICI therapy. Cytokine receptor 3 (C-X-C Motif Chemokine Receptor 3, CXCR3) pathway has been reported to play an important role in the migration, activation, and response of immune cells.
View Article and Find Full Text PDFA large proportion of anti-tumor immunity research is focused on major histocompatibility complex class I (MHC-I) molecules and CD8 T cells. Despite mounting evidence has shown that CD4 T cells play a major role in anti-tumor immunity, the role of the MHC-II molecules in tumor immunotherapy has not been thoroughly researched and reported. In this study, we defined a MHC-II signature for the first time by calculating the enrichment score of MHC-II protein binding pathway with a single sample gene set enrichment analysis (ssGSEA) algorithm.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitors (ICIs) have shown remarkable success in treating skin cutaneous melanoma (SKCM); however, the response to treatment varies greatly between patients. Considering that the efficacy of ICI treatment is influenced by many factors, we selected the Fibrosheath interacting protein 2 (FSIP2) gene and systematically analyzed its potential to predict the efficacy of ICI treatment.
Methods: Patient data were collected from an ICI treatment cohort ( = 120) and a The Cancer Genome Atlas (TCGA)-SKCM cohort ( = 467).